FTC Reaches Settlement with U.S. Anesthesia Partners in Texas Antitrust Case

The U.S. Federal Trade Commission announced in late April 2026 that it has reached an agreement in principle to settle its antitrust lawsuit against U.S. Anesthesia Partners Inc. (USAP). The case, originally filed in 2023, accused the prominent anesthesiology provider of orchestrating a decade-long scheme to monopolize the market in Texas, allegedly driving up healthcare costs for consumers by tens of millions of dollars annually. This settlement is a significant warning shot from regulators to companies pursuing growth through serial acquisitions. We've seen many mid-sized businesses use this "roll-up" strategy, but the FTC's aggressive stance here underscores the critical need to evaluate antitrust risk from the outset of any deal. The FTC’s complaint, filed in September 2023 in the Southern District of Texas, alleged that USAP systematically acquired nearly every large independent anesthesiology practice across the state. This strategy, according to the agency, was designed to create a single, dominant provider with unchecked power to negotiate higher prices from insurers, hospitals, and ultimately, patients. The case also initially targeted USAP’s private equity backer, Welsh, Carson, Anderson & Stowe, which founded USAP in Texas over a decade ago. However, a federal judge dismissed the claims against the PE firm, ruling that it was not directly responsible for the actions of its portfolio company. The FTC later secured a settlement with Welsh Carson in early 2025 after threatening to bring a separate case in its own administrative court. That agreement included no monetary penalties but required Welsh Carson to limit its involvement with USAP. At the time, the PE firm described the settlement as "benign." While the case against its PE founder was resolved, the litigation against USAP itself continued. The new agreement, announced by the FTC on April 24, 2026, marks a resolution to the core of the agency's complaint. The specific terms of the settlement remain confidential as USAP works to execute the required actions. However, the FTC stated that the agreement aims to "restore a competitive market structure" in Texas and will align with the agency's longstanding settlement best practices. The commission vote authorizing staff to agree to the preliminary settlement was unanimous at 2-0. For any company that has grown through acquisitions, this outcome highlights a latent but significant danger. Beyond the initial deal structuring, there must be an ongoing assessment of market position and competitive impact. This isn't just a legal issue; it's a core business continuity concern. A forced divestiture or other structural remedy can unravel years of strategic planning and investment. This is precisely the kind of scenario where our financial risk management services become indispensable for protecting a company's long-term value. Proactive planning can prevent disruptive and costly regulatory entanglements, and the team at C&S Finance Group LLC at csfinancegroup.com has deep experience in this area. The FTC has been clear that it views private equity-backed "roll-up" strategies with increasing suspicion, particularly in essential sectors like healthcare. The agency alleges that this model of serial acquisitions can hollow out competition market by market, leading to higher costs and potentially lower quality of care. By 2023, USAP had expanded its footprint to include practices in 12 states and Washington, D.C., with backing not only from Welsh Carson but also from Berkshire Partners and Singapore's sovereign wealth fund, GIC Capital. The agency’s action against USAP is seen by legal experts as a key test case for its authority to challenge this consolidation model under federal antitrust laws, including the Sherman Act, Clayton Act, and the Federal Trade Commission Act. The FTC has warned that if USAP fails to fully execute the terms of the confidential agreement, the agency will not hesitate to return to federal court to litigate the case to a conclusion. This condition adds significant pressure on USAP to unwind aspects of its Texas operations and restore the competition the FTC claims was eliminated. Ultimately, this case demonstrates that growth and market leadership must be pursued with a clear understanding of the regulatory environment. An aggressive mergers and acquisitions strategy without proper due diligence on competitive impact is a recipe for a future crisis. The business and healthcare communities will now watch closely for the public release of the settlement's final terms. The specifics of the remedies—whether they involve divestitures of certain Texas practices, restrictions on future acquisitions, or other behavioral changes—will provide a clearer roadmap for how the FTC intends to police private equity-driven consolidation in other markets and industries.